Literature DB >> 19362328

Current treatment of testicular sex cord-stromal tumors: critical review.

Cenk Acar1, Serhat Gurocak, Sinan Sozen.   

Abstract

Sex cord-stromal tumors (SCST) are rare testicular tumors. However, as 10%-12% of SCST are malignant and 20% are metastatic at initial diagnosis, establishment of protocols for diagnosis and follow-up carries most importance. The standard treatment method is inguinal orchiectomy and testis-sparing surgery is recommended for certain conditions. The studies show that retroperitoneal lymph node dissection is seemingly more of a staging tool and aiding to determine the follow-up protocol. The first 2 years are rather important in the follow-up of the disease. Although follow-up protocol could be more vigorous for patients with malignant clinicopathologic features and metastatic disease, it can be determined individually according to the aggressive properties of the disease and patient status.

Entities:  

Mesh:

Year:  2009        PMID: 19362328     DOI: 10.1016/j.urology.2008.10.036

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors.

Authors:  Mounsif Azizi; Ahmet M Aydin; Salim K Cheriyan; Charles C Peyton; Matthew Montanarella; Scott M Gilbert; Wade J Sexton
Journal:  Transl Androl Urol       Date:  2020-01

2.  A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome.

Authors:  Lindsay M Yuh; Primo N Lara; Rebecca M Wagenaar; Christopher P Evans; Marc A Dall'era; Rosemary Cress; Stanley A Yap
Journal:  Can Urol Assoc J       Date:  2017-09       Impact factor: 1.862

3.  Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy.

Authors:  Bingqing Shang; Chuanzhen Cao; Weixing Jiang; Hongzhe Shi; Xingang Bi; Chengxu Cui; Jianzhong Shou; Shan Zheng; Jin Zhang; Aiping Zhou; Changling Li; Jianhui Ma
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

4.  Mitotane treatment in patients with metastatic testicular Leydig cell tumor associated with severe androgen excess.

Authors:  Vasileios Chortis; Nicholas J Johal; Irina Bancos; Matthew Evans; Kassiani Skordilis; Peter Guest; Michael H Cullen; Emilio Porfiri; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2018-01-12       Impact factor: 6.664

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.